Advertisement
Advertisement
Alan Oppenheim, managing director

Dermatologically approved, Ego cares for Asian skin

Discovery Reports

Being one of the most trusted skincare companies in a country with harsh weather and the highest skin cancer rate worldwide is testament to Ego Pharmaceuticals' expertise. Ego's extensive knowledge behind the science of skincare enables the company to formulate the best skin therapies for its Australian client base and increasingly its international and Asian customers.

A family-owned company founded in 1953 by chemist Gerald Oppenheim and his wife Rae, a nurse, Ego has developed more than 100 skincare products to remedy a variety of conditions including dermatitis, eczema and rashes.

Ego's outstanding business ethics guarantees exceptional product quality. Aside from following Therapeutic Goods Administration regulations, Ego regularly expands and upgrades its facilities to ensure compliance with legislated and best-in-class manufacturing principles. Its newest expansion project, worth HK$29.9 million, is slated for completion in two years.

"Focus on quality is embedded in everything we do. The Ego spirit embodies value and service for each client and every market we serve," says managing director Alan Oppenheim.

Research and development is central in market-leading, dermatologically recommended products such as Ego's Sunsense sunscreen range and Egocort and DermAid hydrocortisone ranges.

Its QV moisturising and gentle cleansing range is Ego's most popular brand internationally, especially in Asia. The fragrance-free formulation of QV is ideal for Asian skin types, which tend to be oily and irritable.

Ego has gained valuable insights into local market needs through its partnerships with distributors in the region, particularly with its more than 25-year relationship with family-owned Hong Kong company Lision Hong. The distributorship model gave Ego a stable platform to establish subsidiaries in Singapore and Malaysia.

"Our success in Singapore has been a result of our commitment to collaborate with local dermatologists and customers," Oppenheim says. "We want to use this model to expand in Asia, and to serve our new customer base in Malaysia."

Post